ArticleFrontiers in medicine2025
The burden and trends of gastric cancer from 1990 to 2021 in China and globally: a cross-sectional study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A nomogram based on systemic inflammatory markers: development and validation for predicting postoperative overall survival in gastric cancer.Translational cancer research · 2026Article
- Camrelizumab plus CAPOX versus CAPOX for HER2-negative gastric or gastro-oesophageal junction adenocarcinoma: a cost-effectiveness analysis.Frontiers in pharmacology · 2026Article
- The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.Ecancermedicalscience · 2026Review
- Listening to the Past, Shaping the Future: A Data-mining Based and Visual Analysis of Five Decades of Gastric Carcinogenesis Research.Biological procedures online · 2025Article
- Comparative analysis of gastric cancer risk attribution (1990-2021) and 2050 burden projection in China, Japan, and South Korea: an age-period-cohort modeling approach based on the Global Burden of Disease 2021 study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to systematically analyze the trends in gastric cancer burden in China and globally from 1990 to 2021 using data from the Global Burden of Disease (GBD) database, and to forecast future trends from 2022 to 2036. The findings provide a scientific basis for developing targeted gastric cancer prevention and control policies. Methods: Age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASMR) for gastric cancer from 1990 to 2021 were extracted from the GBD database. These data were complemented by GLOBOCAN 2022 statistics to analyze the spatiotemporal characteristics of gastric cancer burden across time, sex, and regions. An autoregressive integrated moving average (ARIMA) model was employed to predict trends from 2022 to 2036. Results: From 1990 to 2021, both ASIR and ASMR for gastric cancer demonstrated significant declines in China and globally. In China, the ASIR decreased from 70.458 per 100,000 in 1990 to 40.125 per 100,000 in 2021 and is projected to further decrease to 25.432 per 100,000 by 2036. Similarly, the ASMR declined from 60.781 per 100,000 in 1990 to 30.214 per 100,000 in 2021 and is forecasted to reach 18.673 per 100,000 by 2036. Globally, the ASIR fell from 35.284 per 100,000 in 1990 to 20.157 per 100,000 in 2021, with a predicted decrease to 12.493 per 100,000 by 2036. Meanwhile, the global ASMR dropped from 30.651 per 100,000 in 1990 to 15.372 per 100,000 in 2021 and is expected to reach 10.284 per 100,000 by 2036. The study also identified significant gender disparities, with males experiencing a substantially higher burden of gastric cancer than females in both China and globally. Furthermore, the age of peak incidence gradually shifted to older age groups, and high-income regions exhibited greater declines in gastric cancer burden compared to low-income regions, highlighting notable regional disparities. Conclusion: Over the past three decades, significant progress has been made in reducing the burden of gastric cancer in China and globally, with declining incidence and mortality rates. These trends are expected to continue in the coming years. However, low-and middle-income countries have seen more limited reductions, with some regions even experiencing increasing burdens. The findings underscore the need for enhanced public health policies focused on preventing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.